Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.

Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.

Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.

L’Oréal plans to acquire Australian luxury beauty brand Aesop from Natura & Co. in third quarter, subject to regulatory approvals, marking its biggest acquisition to date.